Novo Nordisk A/S (NVO) Quote| Reuters.com
Edition:
United States

Novo Nordisk A/S (NVO)

NVO on New York Consolidated

53.01USD
29 Jun 2016
Change (% chg)

$0.78 (+1.49%)
Prev Close
$52.23
Open
$53.12
Day's High
$53.15
Day's Low
$52.72
Volume
1,274,694
Avg. Vol
1,390,610
52-wk High
$60.34
52-wk Low
$46.17

NVO

Chart for NVO

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company's business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1),... (more)

Overall

Beta: 0.81
Market Cap(Mil.): $103,671.20
Shares Outstanding(Mil.): 2,012.56
Dividend: 0.96
Yield (%): 1.83

Financials

  NVO Industry Sector
P/E (TTM): 26.15 33.67 34.69
EPS (TTM): 2.00 -- --
ROI: 89.73 14.91 14.13
ROE: 99.26 15.99 15.35

Swiss stocks - Factors to watch on June 28

ZURICH, June 28 The Swiss blue-chip SMI was seen opening 1.1 percent higher at 7,676 points on Tuesday, according to premarket indications by bank Julius Baer .

Jun 28 2016

BRIEF-Ypsomed Holding collaborates with Novo Nordisk

* Collaborates with Novo Nordisk to provide new solutions in insulin pump therapy Source text: http://bit.ly/293IVRQ Further company coverage: (Gdynia Newsroom)

Jun 28 2016

BRIEF-Novo A/S, main owner of Novo Nordisk, appoints Kasim Kutay as new CEO

* Says appoints Kasim Kutay as new CEO from September 1, 2016

Jun 21 2016

Novo diabetes drug cuts heart risks by less-than-hoped 13 percentage

Novo Nordisk's top-selling diabetes drug Victoza cut the risk of heart attack, stroke and cardiovascular death by 13 percent in a closely watched study, but the result disappointed investors who had hoped for more.

Jun 14 2016

UPDATE 2-Novo diabetes drug cuts heart risks by less-than-hoped 13 pct

* Investors had hoped for bigger benefit, shares off 5 pct (Adds further reaction, latest shares)

Jun 14 2016

BRIEF-Novo Nordisk reports positive results from semaglutide trial

* Says semaglutide demonstrated superior improvements in glycaemic control vs rivals sitagliptin and exenatide ER in two clinical trials in adults with type 2 diabetes

Jun 12 2016

U.S. panel backs approval of Sanofi combination diabetes drug

One day after recommending approval of a new diabetes drug made by Novo Nordisk A/S, a U.S. advisory panel on Wednesday recommended approval of a similar product made by Sanofi SA.

May 25 2016

UPDATE 2-U.S. panel backs approval of Sanofi combination diabetes drug

May 25 One day after recommending approval of a new diabetes drug made by Novo Nordisk A/S, a U.S. advisory panel on Wednesday recommended approval of a similar product made by Sanofi SA.

May 25 2016

European shares hit new 4-week high, Novo Nordisk leads

LONDON, May 25 European shares climbed to a new four-week high on Wednesday, with Novo Nordisk leading the market higher after a U.S. advisory panel recommended approval of its new diabetes drug, while higher copper prices lifted miners.

May 25 2016

FDA panel recommends approval of Novo Nordisk diabetes drug

A U.S. advisory panel on Tuesday recommended approval of a new diabetes drug made by Novo Nordisk A/S that combines two of its existing treatments in a fixed-dose combination designed to be both effective and convenient.

May 25 2016

Competitors

  Price Chg
Sanofi SA (SASY.PA) €74.30 +1.48
Eli Lilly and Co (LLY.N) $78.15 +3.00

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.